Photo taken from Sarah Sammons/X
Feb 7, 2024, 14:13
Sarah Sammons: When rendering a 2nd opinion that is different from a patients local oncologist, it should be data driven/implementable.
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on X/Twitter:
“To my academic colleagues,
When rendering a 2nd opinion that is different from a patients local oncologist, it should be data driven/implementable. If not FDA approved, the pt should be alerted to possible access issues. Message From,
My non-academic brilliant Med Onc friends”
When rendering a 2nd opinion that is different from a patients local oncologist, it should be data driven/implementable. If not FDA approved, the pt should be alerted to possible access issues. Message From,
My non-academic brilliant Med Onc friends”
Source: Sarah Sammons/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12